Clinical observation of EGFR-TKI in advanced non small cell lung cancer patients treated with EGFR-TKI
LV Qiaomei
JIN Chunying
ZHANG Hongjuan
JING Lei
Abstract：Objective To observe the therapeutic effect and safety of epidermal growth factor receptor and tyrosinase inhibitor ( EGFR-TKI ) in the treatment of patients with advanced EGFR-TKI resistance to non small cell lung cancer ( NSCLC) .Methods Collected advanced 79 EGFR-TKI resistant NSCLC patients from January 2010 to December 2013 in Liao-ning Dandong Central Hospital, they were randomly divided into sequential group (first chemotherapy, then EGFR-TKI treat-ment) with 39 cases and chemotherapy group (treated with chemotherapy) with 40 cases, compared two groups'tumor mark-ers, near future curative effect, long-term efficacy and adverse reactions.Results Short term efficacy response rate (20.5%) in the sequential chemotherapy group (10.0%) was higher than chemotherapy group, but the difference was not statistically significant ( P >0.05); sequential group overall response rate (74.4%) was significantly higher than that chemotherapy group (50.0%), the difference was statistically significant ( P <0.05).Sequential progression-free median survival time (PFS) was (3.4 ±0.9) months, which was significantly longer than chemotherapy group (2.5 ±0.8) months ( t =3.981, P <0.05).Sequential group's overall survival time (OS) was (6.4 ±1.2) months, which was significantly longer than chemotherapy group (4.3 ±1.5) months, and the difference was statistically significant ( t =4.182, P <0.05).After treat-ment, serum carcinoembryonic antigen ( CEA) , neuron-specific enolase ( NSE) , cytokeratin 19 fragment ( CYFRA21-1 ) in sequential group were significantly lower than the chemotherapy group ( P <0.05) .Between the two groups, the incidence of adverse reactions and the severity did not show significant differences ( P >0.05).Conclusion After chemotherapy, using EGFR-TKI treatment for advanced EGFR-TKI resistant NSCLC patients can prolong the survival time of patients and it is safe and reliable.
Keywords：Epidermal growth factor receptor and tyrosinase inhibitorDrug resistanceNon small cell lung cancerSequential chemotherapy
Publication Date：2016-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 280-283,291 )